alexa Targeted therapy for locally advanced renal cell carcinoma.
Oncology

Oncology

Journal of Integrative Oncology

Author(s): Jonasch E, Tannir NM, Jonasch E, Tannir NM, Jonasch E, Tannir NM, Jonasch E, Tannir NM

Abstract Share this page

Abstract A number of molecularly targeted agents are now available for patients with metastatic renal cell carcinoma. Their role in locally advanced disease is not well defined, and the mechanisms of progression in the high-risk patient are poorly understood. For an agent to be effective in locally advanced renal cell carcinoma it needs to be able to downstage primary tumors, and to prevent the formation of metastases. In this review, we summarize clinical trials assessing the ability of these new agents to cytoreduce primary tumors, and explore available evidence on their ability to prevent the formation of metastases. Ongoing adjuvant clinical trials assessing molecularly targeted agents in the high-risk setting will provide valuable information on their utility in this patient population. Future trials using agents with optimized cytoreductive capabilities in conjunction with therapies capable of preventing metastatic dissemination may improve the outcomes of patients with locally advanced renal cell carcinoma. This article was published in Target Oncol and referenced in Journal of Integrative Oncology

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords